Pharma
Stopping growth factors that create damage in the eye has proven lucrative. Lucentis (ranibizumab, Roche/Genentech) achieved sales of $1.8 billion in 2016 outside the US…
Read More
Spark Therapeutics is riding a double shot of positive news about its gene therapy treatment for RPE65-mediated inherited retinal disorders that’s given its stock a…
Read More
With another failed trial of its glaucoma candidate trabodenoson in hand, Inotek Pharmaceuticals Corp. is pondering options that could include selling the company, but finding…
Read More
As Applied Genetic Technologies Corporation (AGTC) heads into the summer with encouraging results for two of its lead candidates using the adeno-associated virus-based gene technology…
Read More
When Novartis last week announced positive outcomes from two Phase III trials for new age-related macular degeneration (AMD) drug brolucizumab (RTH258), it seemed the other…
Read More
With the recent report of successful top-line Phase III results of its fixed-dose glaucoma candidate Roclatan, Aerie Pharmaceuticals Inc. has seen its stock price soar…
Read More
During the run-up to the launch of Shire’s dry eye drug Xiidra (lifitegrast), it seemed as though everyone was wondering what kind of threat –…
Read More
Coming off word that the Phase I/IIa clinical trial of its novel anti-VEGF candidate for treatment of age-related macular degeneration exceeded expectations, along with positive…
Read More
Soon-to-be FDA commissioner, Scott Gottlieb, MD, is well positioned to understand where the medtech and biotech communities are coming from. He’s been a partner at…
Read More
Medical marijuana has quickly gained acceptance as a viable treatment for a variety of health conditions, such as the side effects of chemotherapy, the neurodegenerative…
Read More
Virtual reality has been used to train surgeons, to evaluate balance control and associated fall risk in glaucoma patients, and, more recently, to create simulations…
Read More
Late last year, when developers of agents that combined anti-platelet derived growth factor with an anti-vascular endothelial growth factor (anti-PDGF/anti-VEGF) to treat wet age-related macular…
Read More
SUBSCRIBE TO OIS NEWS
Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.
We respect your privacy and promise to never send you spam.
![OIS-ANTERIOR-NEW-DATE-750x420[4300]](https://ois.net/wp-content/uploads/2020/03/OIS-ANTERIOR-NEW-DATE-750x4204300.jpg "OIS-ANTERIOR-NEW-DATE-750x420[4300]")